請輸入關鍵字:

熱門搜尋:

Arthur D. Little Report Explores Impact of “Ultra-targeted” Healthcare

日期: 2019年5月7日 下午4:15

All segments of healthcare will need to adapt to unprecedented change driven by technological advancements in areas such as molecular biology, AI and digitalization

BOSTON--(BUSINESS WIRE)-- As pivotal changes in healthcare and drug development gain traction, new analysis from Arthur D. Little (ADL) highlights that all sectors of the industry must evolve their business and operating models in the coming decade.

From genomic treatments to Artificial Intelligence in diagnostics to leaps in curative medicine, the healthcare ecosystem is facing unprecedented change. ADL’s forward-looking assessment is captured in a new Report, “Future Health: How the industry will move from ‘one size fits all’ to ultra-targeted care.”

Several critical shifts are pushing major players across the world to adapt:

  • Targeted treatments are changing the way drugs are brought to market, with greater emphasis on patients’ biological make-ups. Already, 22% of drugs currently in development specify a biomarker as criteria for inclusion, according to ADL research.
  • ADL projects the global consumer genetic testing market will reach $50B by 2026, leading to an abundance of genomic data that will be available to guide prevention, diagnosis, and treatment.
  • Certain chronic diseases will become more curable or treatable, and patients with access to more data will have greater opportunity to prevent or manage their conditions.
  • Long-term care will continue to shift away from hospitals, which will in turn move their model from surgeries and long-term chronic care to a physician-led approach to curative therapies, and may lead them to consider onsite device and drug manufacturing.

Craig Wylie, Managing Partner at ADL in the United States, notes: “Incredible advances in genomics and diagnostics are leading to a future that will impact the entire breadth of the healthcare industry. Companies are in the early stages of evolving their approach to clinical trials, commercial models, and care provision.”

“The pace of change and the associated costs will be staggering,” continued Wylie. “The most successful organizations across all segments of the healthcare ecosystem will be those that adapt their business models, rethink their operations, and place an emphasis on collaboration and partnerships.”

To download the Report, please visit: www.adl.com/FutureHealth

Contacts

Cate Bonthuys
Catalyst Comms
cate@catalystcomms.co.uk
Tel: +44 7746546773

財華網所刊載內容之知識產權為財華網及相關權利人專屬所有或持有。未經許可,禁止進行轉載、摘編、複製及建立鏡像等任何使用。

如有意願轉載,請發郵件至 content@finet.com.hk,獲得書面確認及授權後,方可轉載。

下載APP 下載財華財經APP,把握投資先機
更多精彩内容,請點擊: 財華網(https://www.finet.hk/) 財華智庫網(https://www.finet.com.cn) 現代電視FINTV(http://www.fintv.hk)

視頻

快訊

14:16
中國建築興業(00830.HK)年度股東應佔溢利同比降63.5%至2.37億港元 末期​息1港仙
14:15
【異動股】炭黑板塊下挫,龍星科技(002442.CN)跌7.67%
14:03
光大環境(00257.HK)漲超5% 年度權益持有人應佔盈利升16%至39.25億港元
13:30
【異動股】資源開采概念板塊下挫,新錦動力(300157.CN)跌10.42%
13:30
【異動股】港股跌幅榜前十,大唐西市(00620.HK)跌42.74%,超人智能(08176.HK)跌33.33%
13:30
【異動股】港股漲幅榜前十,廣合科技(01989.HK)漲43.16%,萬順集團控股(01746.HK)漲34.04%
13:23
太興集團(06811.HK)年度股東應占溢利同比增長72.3% 末期息5港仙
13:15
【異動股】昨日高換手板塊下挫,東方國信(300166.CN)跌10.39%
13:15
【異動股】逆變器板塊拉升,上能電氣(300827.CN)漲20.01%
12:57
大唐西市(00620.HK)停牌